"Terry-Ann has been an invaluable member of our team over the last five years, and her leadership was instrumental in the success of our IPO, the build-out of our finance and corporate affairs functions, and the development of Beam's organization and culture," said John Evans, chief executive officer at Beam. "During her tenure, we have successfully raised significant capital to invest in our innovative platform technologies, our manufacturing capabilities, and now our rapidly growing clinical and research ...

Here are some reasons why investors should consider betting on Beam Therapeutics stock. Hematology Program Picking Up Pace: The company is pursuing an ex vivo, autologous transplant-based approach for SCD and beta-thalassemia. It is currently developing BEAM-101 in the phase I/II BEACON study for SCD. Dosing and engraftment for the three patients in the sentinel cohort of the BEACON study have been completed. Data from multiple patients in the study is expected in the second half of 2024. Image Source: Zack ...

A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. As such, the Zacks rating upgrade for Beam Therapeutics is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price. The change in a company's future earnings potential, as reflected in earnings estimate revisi ...

VICI stock currently trades at a P/E ratio of just 11x, significantly below the average of 30x for the S&P 500 index. Despite the VICI share price declining 13% year-to-date (YTD), all 21 analysts recommend buying at current levels as the company continues to deliver consistent revenue growth. Jefferies analyst David Katz has a price target with a potential 58% upside from current levels. Identifying stocks capable of increasing investment value 10x can prove tricky. However, those with solid sales growth a ...

With the progression of modern medicine, and the continuous discoveries in the realm of gene editing, investing early in the technology could be a game changer for long-term returns if selecting the best gene editing stocks to buy. That's because unlike more standard therapeutics such as antibiotics, antivirals and vaccines gene editing is a permanent solution most of the time. It changes the base instructions of the human body for how the body is maintained and protected. CRISPR Therapeutics (CRSP) When it ...

The open-label, dose-escalation study will investigate the safety, pharmacodynamics, pharmacokinetics and efficacy of BEAM-302 for the given indication. The study is designed to identify the optimal dosage of BEAM302. BEAM received clearance for its clinical trial authorization application from the United Kingdom Medicines and Healthcare Products Regulatory Agency for BEAM-302 in March 2024. BEAM is also developing another pipeline candidate in its genetic disease portfolio, BEAM-301. The company is looking ...

CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the first patient was treated with BEAM-302, an investigational in vivo base editing medicine designed to precisely correct the underlying cause of severe alpha-1 antitrypsin deficiency (AATD), that is currently being evaluated in a Phase 1/2 clinical trial. "Treating the first patient with BEAM-302 is an important mil ...

About BEAM-302 It is estimated that approximately 100,000 individuals in the United States (U.S.) have two copies of the Z allele, known as the PiZZ genotype, although only 10-15% of all patients are thought to have been diagnosed. There are currently no curative treatments approved for patients with AATD, and the only approved therapy in the U.S., intravenous AAT protein replacement, has not been shown to prevent ongoing lung function decline and destruction in patients. Cautionary Note Regarding Forward-L ...

Beam designed its automated CD34+ HSPC process for manufacturing of BEAM-101 to have the flexibility for a wide range of patient-starting material and variable cell numbers, while maintaining robust cell yield and high drug product quality suitable for use in the BEACON Phase 1/2 clinical trial. Today's data highlight the following: About Beam Therapeutics | --- | |---------------------| | | | Contacts: | | Investors: | | Holly Manning | | Beam Therapeutics | | hmanning@beamtx.com | | Media: | | Dan Budwick ...

"The manufacturing of autologous cell and gene therapies, particularly for sickle cell disease, is complex and has significant implications for product quality as well as the patient experience," said Giuseppe Ciaramella, Ph.D., president of Beam. "The data presented today at EHA demonstrate that our optimized process for the manufacturing of BEAM-101, which integrates key technologies and automation improvements, has achieved reproducible and robust product yields and viability that meet demanding high-qua ...